KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Gross Margin (2017 - 2025)

Historic Gross Margin for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 81.95%.

  • Biomarin Pharmaceutical's Gross Margin rose 72200.0% to 81.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 81.32%, marking a year-over-year increase of 24700.0%. This contributed to the annual value of 79.67% for FY2024, which is 16600.0% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Gross Margin is 81.95%, which was up 72200.0% from 81.82% recorded in Q2 2025.
  • Biomarin Pharmaceutical's Gross Margin's 5-year high stood at 81.95% during Q3 2025, with a 5-year trough of 72.72% in Q4 2022.
  • Moreover, its 5-year median value for Gross Margin was 77.48% (2022), whereas its average is 77.71%.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Gross Margin surged by 142700bps in 2021, and later crashed by -32500bps in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Gross Margin (Quarter) stood at 73.38% in 2021, then decreased by -1bps to 72.72% in 2022, then grew by 8bps to 78.66% in 2023, then rose by 4bps to 81.78% in 2024, then grew by 0bps to 81.95% in 2025.
  • Its Gross Margin was 81.95% in Q3 2025, compared to 81.82% in Q2 2025 and 79.66% in Q1 2025.